The New England Journal of Medicine has recently reported that use of PARP inhibitors with patients who have prostate cancer has proven to be extremely successful, with most of the 60 patients involved in the study experiencing tumor shrinkage, with few, if any, side effects. Its believed that PARP inhibitors may regulate the genes BRCA1 and BRCA2, the 2 genes primarily responsible for breast cancer. So what do you guys think? 60 patients is an extremely small study, do PARP inhibitors have a future in cancer research, or is this study a fluke? Could PARP inhibitors be the next big thing for the pharmaceutical companies?[Article]
Thursday, June 25, 2009
New class of Anti-cancer drugs brings hope?
The New England Journal of Medicine has recently reported that use of PARP inhibitors with patients who have prostate cancer has proven to be extremely successful, with most of the 60 patients involved in the study experiencing tumor shrinkage, with few, if any, side effects. Its believed that PARP inhibitors may regulate the genes BRCA1 and BRCA2, the 2 genes primarily responsible for breast cancer. So what do you guys think? 60 patients is an extremely small study, do PARP inhibitors have a future in cancer research, or is this study a fluke? Could PARP inhibitors be the next big thing for the pharmaceutical companies?[Article]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment